CABANA

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

ANZCTR Trial ID: NCT00911508

CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for AF.

The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients with untreated or incompletely treated AF.

Please contact Jonathon Foote for more information. 

  • Professor Sanders says...

     
    Atrial fibrillation is a consequence of several reversible risk factors - high blood pressure, diabetes, obesity, sleep apnoea, and excessive alcohol. Your management of atrial fibrillation must include strict control of these risk factors.